A randomized controlled clinical study for intranasal dexmedetomidine on ultrasound-guided brachial plexus block

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900023484

Enrollment

Unknown

Registered

2019-05-31

Start date

2019-06-01

Completion date

Unknown

Last updated

2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ultrasound-guided brachial plexus block

Interventions

1:0.5ug/kg intranasal dexmedetomidine

2:1ug/kg intranasal dexmedetomidine

3:1.5ug/kg intranasal dexmedetomidine

4:equal volume of intranasal saline

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients undergoing ultrasound-guided brachial plexus block, ASA I~II level, aged 18-60 years, body mass index 18~24kg/m2, sugery time between 1-2 hours, signed informed consent.

Exclusion criteria

Exclusion criteria: Bradycardia, hypotension, hypovolemia, increased intracranial pressure, pneumothorax, chronic obstructive pulmonary disease, asthma, allergic rhinitis, excessively thick nasal hair, high blood pressure, heart disease, liver and kidney dysfunction, long-term use Sedative medicine, etc..

Design outcomes

Primary

Measure	Time frame
Rmasay score;APAIS score;VAS score;satisfaction score of patients;	—

Secondary

Measure	Time frame
vital signs;adverse reactions;onset time of brachial plexus block;	—

Countries

China

Contacts

Public ContactLong Yan

Wuxi People's Hospital

2313987158@qq.com+86 18268028476

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026